Manfred Rüdiger

Manfred Rüdiger

Function at HeartBeat.bio: Member of the Supervisory Board

Manfred is in executive functions in the biotech industry since 20+ years. He led the EUR 50M financing of CatalYm in 2020. As Chairman of apceth Biopharma, he led the negotiations during the acquisition of apceth by Hitachi in 2019. Prior, he was CEO of Kiadis Pharma N.V. which he restructured and led to its IPO on Euronext in 2015. He was CSO of Cardion and CEO of Igeneon until 2005. He is on the Supervisory Board of 4SC AG and the Advisory Board of the ALS Investment Fund. He holds a PhD in biochemistry for research at the MPI for Biophysical Chemistry, Göttingen, Germany.

„HeartBeat.bio is an exciting start-up based on top-notch, leading-edge science around cardiac organoids. I believe that organoid disease models and screening tools will become a key part of innovative cardiovascular research and drug development. I am excited to be part of this effort and to work with the the team.“